Pharmaceutical - tofacitinib


Current filters:


Popular Filters

Mixed Ph III data for Pfizer’s tofacitinib vs Enbrel in plaque psoriasis


US pharma giant Pfizer has announced detailed results from OPT Compare (A3921080), a Phase III study…


Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib


Pfizer has announced mixed top-line results from two Phase III clinical trials of tofacitinib for the…

DermatologicalsNorth AmericaPfizerPharmaceuticalResearchtofacitinibXeljanz

Novartis' secukinumab demonstrates superiority to rival Enbrel in psoriasis study


Swiss drug major Novartis (NOVN: VX) has announced results from a Phase III psoriasis study which showed…

AbbVieAmgenDermatologicalsEnbrelHumiraJanssen BiotechNovartisPharmaceuticalsecukinumabStelara Injectiontofacitinib

Newly approved tofacitinib slows rheumatoid arthritis joint damage


A Phase III clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression…


FDA approves Pfizer's Xeljanz for rheumatoid arthritis


Having in the summer put back its "action date" due to a request for additional analysis of the existing…

Anti-Arthritics/RheumaticsNorth AmericaPfizerPharmaceuticalRegulationtofacitinibXeljanz

FDA puts back action date on Pfizer's tofacitinib by three months


Pfizer (NYSE: PFE), the world's largest drugmaker by sales, yesterday revealed that the US Food and Drug…

Anti-Arthritics/RheumaticsNorth AmericaPfizerPharmaceuticalRegulationtofacitinib

Pfizer RA drug candidate tofacitinib shows promise in ulcerative colitis


Patients with moderately to severely active ulcerative colitis treated with drug behemoth Pfizer's (NYSE…


Positive new data for Pfizer's tofacitinib; possible regulatory delay


Pfizer (NYSE:PFE), the world's largest drugmaker by sales, yesterday released positive top-line results…

Anti-Arthritics/RheumaticsNorth AmericaPfizerPharmaceuticalRegulationResearchtofacitinib

FDA advisory backs Pfizer's tofacitinib for RA


The US Food and Drug Administration's Arthritis Advisory Committee yesterday voted eight to two to recommend…

Anti-Arthritics/RheumaticsNorth AmericaPfizerPharmaceuticalRegulationtofacitinib

Ulcerative colitis drug market to reach $3 billion by 2020


The ulcerative colitis drug market will experience moderate growth over the next decade, increasing from…

Gastro-intestinalsHumiraMarkets & MarketingPharmaceuticalRemicadeSimponi Injectiontofacitinibvedolizumab

Unexpectedly strong data for Galapagos rheumatoid arthritis drug candidate


Shares of Belgium-based biotech firm Galapagos (Euronext: GLPG) jumped 22% on Tuesday and a further 12%…


Many European dermatologists want more post-marketing data before Rxing Pfizer’s Janus


At least half of surveyed dermatologists across the EU5 (France, Germany, Italy, Spain and the UK) will…

BiotechnologyDermatologicalsEuropeJanusMarkets & MarketingPfizerPharmaceuticaltofacitinib

Back to top